The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 2, pp. 192-195. DOI 10.1345/aph.10184
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dixon, A.
Right arrow Articles by Wall, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dixon, A.
Right arrow Articles by Wall, G.

Research Articles

Probable colchicine-induced neutropenia not related to intentional overdose

AJ Dixon and GC Wall

OBJECTIVE: To report a case of neutropenia caused by colchicine not associated with intentional overdose or with preceding severe gastrointestinal symptoms. CASE SUMMARY: A 68-year-old white man was admitted to the hospital with intractable pain from an acute attack of gout. The patient was treated with standard doses of oral colchicine for several days. He experienced mild loose stools, but no severe diarrhea or nausea during treatment. The patient then developed severe neutropenia, with an absolute neutrophil count of 240 cells/mm3. His white blood cell count returned to normal after discontinuing colchicine and administering filgrastim. DISCUSSION: Although colchicine is commonly associated with neutropenia in cases of intentional or accidental overdose, the patient developed this adverse effect after being treated with doses commonly used for the acute treatment of gout. In addition, this patient had taken low-dose colchicine for many years without experiencing hematologic adverse effects. CONCLUSIONS: Colchicine is often an attractive alternative to nonsteroidal antiinflammatory agents for the treatment of gout, especially in patients at risk for renal impairment or gastropathy. Our case illustrates that colchicine treatment can cause hematologic adverse effects; the clinician should monitor cell counts in patients receiving this agent, especially at the higher doses used for acute treatment of gout.


This article has been cited by other articles:


Home page
 LupusHome page
M Lidar, G Zandman-Goddard, Y Shinar, N Zaks, A Livneh, and P Langevitz
Systemic lupus erythematosus and familial Mediterranean fever: a possible negative association between the two disease entities - report of four cases and review of the literature
Lupus, July 1, 2008; 17(7): 663 - 669.
[Abstract] [PDF]

Home page
 PediatricsHome page
T. Kallinich, D. Haffner, T. Niehues, K. Huss, E. Lainka, U. Neudorf, C. Schaefer, S. Stojanov, C. Timmann, R. Keitzer, et al.
Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement
Pediatrics, February 1, 2007; 119(2): e474 - e483.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.